STELARA® (ustekinumab) for Psoriatic Arthritis Treatment

Skip to main content

For US Healthcare Professionals
Important Safety Information
Prescribing Information
Medication Guide
Medical Information Center
Janssen CarePath
Patient Site

CHOOSE INDICATIONPsoriatic Arthritis

Ulcerative Colitis
Crohn’s Disease
Plaque Psoriasis
Psoriatic Arthritis

Efficacy
Safety Profile
- 16-week Safety
- 108-week Safety
Dosing
- Administration
- Dosing Comparison
Mechanism
of Action
ACCESS &
SUPPORT
Resources
- PRACTICE RESOURCES
- PATIENT RESOURCES

sites

Enter terms

For US Healthcare Professionals
Important Safety Information
Prescribing Information
Medication Guide
Medical Information Center
Janssen CarePath
Patient Site

homepage-banner-desktop

banner-mobile-home

WHEN STELARA^® IS THE RIGHT CHOICE FOR YOUR ADULT PATIENTS
WITH ACTIVE PSORIATIC ARTHRITIS (PsA), BUT THEY MAY HAVE...

MORE ON
THEIR MINDS

THAN THEIR PsA MEDICATION

Take self-injection off their plate with the STELARA® 45-mg vial
and ensure that they are taking their medication as prescribed.

ACCESS & AFFORDABILITY

Learn about access and savings for eligible patients.

© Janssen Biotech, Inc. 2021. All rights reserved.

cp-184846v1

This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. This site is intended for use by Healthcare Professionals of the United States and Puerto Rico. Janssen Biotech, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Medical Information Center 0

Do not sell my personal information

Last Updated July 2021

Study Design

PSUMMIT I was a multicenter, randomized, double-blind, placebo-controlled study in 615 adult patients with active PsA for ≥6 months despite treatment with nonsteroidal anti-inflammatory drug (NSAID) or disease-modifying antirheumatic drug (DMARD) therapy; patients were biologic-naïve. PSUMMIT II was a multicenter, randomized, double-blind, placebo-controlled study in 312 adult patients with active PsA for ≥6 months, despite current or previous DMARD and/or NSAID therapy, and who may have been previously treated with biologic anti-TNF agent(s). In both studies, active PsA was defined as ≥5 swollen joints, ≥5 tender joints, and C-reactive protein ≥0.3 mg/dL. Patients had active plaque psoriasis, or a documented history of plaque psoriasis, and could be categorized in at least 1 of the PsA subsets (distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis). Patients who previously had been treated with anti-TNFα therapy, or had received systemic therapy, received systemic immunosuppressives, or DMARDs other than MTX within 4 weeks prior to the first study dose, were to be excluded from participation. Stable doses (≤25 mg/week) of MTX at study entry, stable oral corticosteroid doses equivalent to ≤10 mg/day of prednisone, and NSAIDs were permitted. Patients were randomized to receive STELARA® 45 mg, STELARA® 90 mg, or placebo as a subcutaneous injection at Weeks 0 and 4 and every 12 weeks thereafter. At Week 16, patients with <5% improvement from baseline in both tender and swollen joint counts in the 45-mg and placebo groups were eligible for early escape and received STELARA® 90 mg and 45 mg, respectively. Patients randomized to placebo who did not qualify for early escape were to cross over to receive STELARA® 45 mg at Weeks 24 and 28, followed by injections every 12 weeks thereafter. The primary endpoint was the percentage of patients achieving ACR20 response at Week 24. Patients were followed for efficacy through Week 100 and for safety through Week 108. Investigative study sites and patients remained blinded to treatment assignment until the last enrolled subject completed Week 108. Although treatment failure rules were the same, criteria for a treatment failure changed after Week 52 because the protocol allowed concomitant use of DMARDs besides MTX, systemic immunosuppressant, or additional corticosteroids starting at Week 52. Those medications were therefore not considered prohibited after Week 52 defining of treatment failures.^1-4

Loading Common Footer...